Article

Improvement of influenza vaccine strain A/Vietnam/1194/2004 (H5N1) growth with the neuraminidase packaging sequence from A/Puerto Rico/8/34.

State Key Laboratory of Respiratory Diseases, Institute of Respiratory Diseases, Guangzhou College of Medicine, Guangzhou, China.
Human vaccines & immunotherapeutics 02/2012; 8(2):252-9. DOI:10.4161/hv.18468 pp.252-9
Source: PubMed

ABSTRACT H5N1 influenza candidate vaccine viruses were developed using the "6+2" approach. The hemagglutinin (HA) and neuraminidase (NA) genes were derived from the popular H5N1 virus and the remaining six internal segments were derived from the A/Puerto Rico/8/34 strain (H1N1, PR8). However, some of these candidate strains have been reported to produce relatively low yields in vaccine manufacture. In this study, we found that the NA vRNA of the A/Vietnam/1194/2004 strain (H5N1, VN1194) was poorly packaged into recombinant viruses with a backbone of PR8 genes, which resulted in the formation of defective virions that did not include the NA vRNA in the genome. Using recombinant DNA techniques, we constructed a chimeric NA gene with the coding region of VN1194 NA flanked by the packaging signal sequence of the PR8 NA gene (41 bp form the 3' end of the vRNA and 67 bp from the 5' end). The packaging of the NA vRNA was restored to normal levels in the recombinant viruses containing the chimeric NA gene. Recombinant viruses containing the chimeric NA replicated much better in chicken embryonated eggs than viruses with the wild-type NA from VN1194. These findings suggest a novel strategy to improve in ovo growth of vaccine strains and to increase the number of vaccine doses available to save people if a pandemic were to occur.

0 0
 · 
0 Bookmarks
 · 
31 Views

Keywords

candidate strains
 
chicken embryonated eggs
 
chimeric NA gene
 
chimeric NA replicated
 
H5N1 influenza candidate vaccine viruses
 
hemagglutinin
 
low yields
 
NA vRNA
 
normal levels
 
packaging signal sequence
 
popular H5N1 virus
 
PR8 NA gene
 
recombinant DNA techniques
 
recombinant viruses
 
remaining six internal segments
 
vaccine doses available
 
vaccine strains
 
viruses
 
vRNA
 
wild-type NA